Key facts
- VisCardia’s last known valuation is $182.0M (Nov 2025).
- It has raised $34.6M across 5 recorded rounds; the latest was Early Stage VC ($9.5M) in Oct 2025.
- Notable investors include MedTech Innovator, Kinetic Capital Partners.
- VisCardia has filed 6 Form Ds with the SEC since 2016, most recently Apr 2022 ($1.5M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 5 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for VisCardia
Funding rounds
5 roundsAbout VisCardia
Developer of an implantable medical device designed to treat thoracic cardiac diseases. The company's device is based on an implantable electronic sensor and electrode system that delivers chronic electrical stimulation for mediating thoracic pressure augmentation, enabling patients to use their thoracic musculature to improve cardiac filling and relieve symptoms of hemodynamic insufficiency.
- Sector
- Healthcare
- HQ
- Beaverton, OR, United States
- Founded
- 2015
- Employees
- 8
- Website
- viscardia.com/
- Ownership
- Privately Held (backing)
VisCardia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in VisCardia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on VisCardia in its N-PORT filings yet. We sweep new filings monthly.